Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ TumorsCIRB: Adult CIRB - Early Phase EmphasisLead Group: ETCTNStatus: ActiveReview Status: Available to Open
